PE-22-28 vs Humanin
Side-by-side comparison of key properties, dosing, and research.
- Summary
- PE-22-28 is a synthetic analog of spadin derived from sortilin, designed to block TREK-1 potassium channels with rapid-onset antidepressant and neurogenic effects. It shows fast-acting depression relief (within 24 hours) and promotes hippocampal neurogenesis.
- Humanin is a mitochondria-derived peptide (MDP) encoded in the 16S rRNA region of the mitochondrial genome. It protects neurons and other cells from apoptosis, improves insulin sensitivity, and declines significantly with age. HNG (S14G-Humanin) is a synthetic analog with 1000x greater potency.
- Half-Life
- Relatively short; CNS effects may persist due to neurogenic mechanisms
- ~4–8 hours (HNG)
- Admin Route
- SubQ, Intranasal
- SubQ
- Research
- —
- —
- Typical Dose
- 200–400 mcg
- 2–8 mg
- Frequency
- Once daily
- 3–5 times per week
- Key Benefits
- Rapid-onset antidepressant effects (within 24 hours)
- Promotes hippocampal neurogenesis
- Improves cognitive performance and memory
- Reduces anxiety and depressive behavior
- Novel mechanism — does not act on serotonin/dopamine/GABA receptors directly
- May help treatment-resistant depression
- Neuroprotective effects
- Neuroprotection against amyloid-beta toxicity (Alzheimer's relevance)
- Inhibits cellular apoptosis
- Improves insulin sensitivity
- Reduces cardiovascular risk markers
- Anti-inflammatory effects
- Correlates with longevity in centenarian studies
- Protects against ischemic injury
- Potential cancer cell apoptosis sensitization
- Side Effects
- Generally well tolerated in animal models
- Limited human data available
- Possible mild headache or transient mood changes at initiation
- Injection site reactions (SC)
- Injection site irritation
- Limited human safety data available
- Stacks With
- —
- —